Wed Nov 28, 2012 1:04pm EST
(Reuters) – Ironwood Pharmaceuticals Inc pronounced a drug to provide irked bowel syndrome with constipation has perceived selling capitulation in Europe.
The drug linaclotide, meant for adults, will be launched in Europe in a initial half of 2013 underneath a code name Constella, a association pronounced in a statement.
Constella perceived U.S. regulatory capitulation in Aug and Ironwood will sell a drug in a United States with a selling partner Forest Laboratories underneath a code name Linzess.
“We don’t see Constella’s opening in Europe as a poignant value motorist for Ironwood,” Ladenburg Thalmann researcher Juan Sanchez wrote in a note to clients.
Sanchez estimates that Constella could move in income of $189 million in 2018.
Shares of Ironwood were adult 2 percent during $10.98 on a Nasdaq on Wednesday afternoon.
(Reporting by Shailesh Kuber in Bangalore; Editing by Supriya Kurane)